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Background: Human Immunodeficiency Virus 1 (HIV-1) and Mycobacterium
Tuberculosis (Mtb) co-infected patients are commonly at risk of immune reconstitution
inflammatory syndrome (IRIS) when initiating antiretroviral treatment (ART). Evidence
indicates that innate immunity plays a role in TB-IRIS. Here, we evaluate the
phenotype of Gamma-delta (γδ) T cells and invariant Natural Killer (iNK) T cells in
tuberculosis-associated IRIS.
Methods: Forty-eight HIV+/TB+ patients (21 IRIS) and three control groups:
HIV–/TB– (HD, n = 11), HIV+/TB– (n = 26), and HIV–/TB+ (n = 22) were studied.
Samples were taken at ART initiation (week 2 of anti-tuberculosis treatment) and at
the diagnosis of IRIS for HIV+/TB+; before ART for HIV+/TB-, and at week 2 of anti-
tuberculosis treatment for HIV–/TB+ patients. γδ T cells and Invariant natural killer T (iNKT)
cells were analyzed by flow cytometry.
Results: Before ART, IRIS, and non-IRIS patients showed a similar proportion of γδpos
T and iNKT cells. HLA-DR on γδpos T cells and δ2posγδpos T cells was significantly higher
in TB-IRIS vs. non-IRIS patients and controls (p < 0.0001). NKG2D expression on γδpos
T cells and the δ2posγδpos T cell subset was lower in HIV+/TB+ patients than controls.
CD158a expression on γδpos T cells was higher in TB-IRIS than non-IRIS (p = 0.02),
HIV+/TB–, and HIV–/TB- patients.
Conclusion: The higher activation of γδposT cells and the γδ2posγδpos T cell subset
suggests that γδ T cells may play a role in the pathogenesis of TB-IRIS.
Keywords: HIV, tuberculosis, immune reconstitution inflammatory syndrome, gamma delta T cells, invariant NKT
cells
Pean et al. γδ T Cells and iNKT Cells in TB-IRIS
INTRODUCTION
Tuberculosis (TB) and Human Immunodeficiency Virus
(HIV) infection are serious global public health concerns.
Mycobacterium tuberculosis (Mtb) primarily infects resident
alveolar macrophages through various immune receptors (e.g.,
C-type lectin mannose receptors and scavenger receptors)
expressed on the cell surface (1). In addition, DC-SIGN
receptors also play a pivotal role in Mtb internalization by
dendritic cells (DC) (2). By infecting antigen-presenting cells,
such as macrophages and DC, Mtb can modulate antigen
presentation, thereby affecting inflammation, DC cross-talk with
other immune cells, and adaptive immune responses (3). Yet,
knowledge of the interactions between Mtb and innate immune
cells is limited. Increased access to antiretroviral therapy (ART)
has significantly improved the clinical outcome of patients
in resource-limited settings. However, between 4 and 54% of
patients develop inflammatory responses, known as immune
reconstitution inflammatory syndrome (IRIS), within the first
few months of ART (4, 5). TB-associated IRIS (TB-IRIS) is
thought to be directed toward Mtb antigens and is characterized
by unexplained worsening or occurrence of symptoms or signs of
TB post-ART initiation. Well-known risk factors associated with
TB-IRIS include: low CD4+ T cell count below 200 cell/mm3
at the time of clinical diagnosis of co-infection (5, 6); short
interval between onset of TB treatment and ART (5, 7); and,
disseminated tuberculosis (5). However, there are no definite
biomarkers to predict or diagnose this syndrome. It has been
suggested that the pathogenesis of TB-IRIS involves both innate
and adaptive immunity (4, 8), but the specific mechanisms of
TB-IRIS pathogenesis remains unclear.
Patients with unmasking TB-IRIS display higher levels of
Natural Killer (NK) cell activation and IL-8 than non-IRIS
or Human Immunodeficiency Virus 1 (HIV-1)-monoinfected
patients (9). Previously, we found that baseline capacity of
NK cell degranulation was significantly higher in TB-IRIS
patients vs. those without the syndrome, indicating a role
of NK cells in the pathogenesis of TB-IRIS (10). Moreover,
modification of the Gamma-delta (γδ) T cell repertoire, a well-
known non-conventional T cell population that plays a role
in the pathogenesis of Mtb infection, has also been reported
in TB-IRIS patients (11). Gamma-delta T cells are innate-like
T lymphocytes encompassing a small fraction (1–5%) of the
circulating T lymphocyte pool. Unlike alpha-beta (αβ) T cells,
γδ T cells express γ, and δ heterodimers of T cell receptors
(TCR) associated with CD3 complexes and can recognize the
lipid and glycolipid antigens produced by Mtb. Gamma-delta T
cells also express various NK cell receptors (including NKG2D,
killer immunoglobulin-like receptors KIRs) that play a role in
the regulation of γδ T cell-mediated immune responses (12)
including: cytolytic activity; pro- and anti-inflammatory cytokine
production; and, the induction of a robust CD8+ T cell response
via γδ T-APC crosstalk (13). The two major γδ T cell subsets are
defined by their Vδ chains: Vδ1 and Vδ2. Most of the circulating
γδ T cell pool is made up of the Vδ2posγδpos subset (14). A higher
proportion of γδ T cells and inversion of the Vδ1pos/Vδ2pos ratio
has been associated with chronic HIV infection (15).
Invariant natural killer T (iNKT) cells, which are CD1d-
restricted glycolipid antigen reactive, can promote cell-mediated
immunity against infection and tumors (16). Activation of iNKT
cells results in rapid production of a large array of cytokines and
chemokines which could be beneficial (16). Indeed, activation
of CD1d-restricted iNKT cells protects against intracellular
bacterial growth in Mtb infected mice (17); however, iNKT
cell activity can also be harmful to the host in some diseases
such as atherosclerosis and allergy (18). In HIV and TB mono-
infections, iNKT cells are depleted and functionally impaired
(19, 20), but partial reconstitution of iNKT cells during ART or
anti-TB therapy has been observed (21). Interestingly, an elevated
proportion of iNKT cell has been reported in TB-IRIS patients vs.
non-IRIS control at the time of IRIS onset (22), but the exact role
of iNKT cells in TB-IRIS is yet to be defined.
Therefore, we studied the peripheral levels, activation, the
repertoire of γδT cells and iNKT cells in TB-IRIS patients relative
to that of non-IRIS patients in the CAMELIA clinical trial (23).
MATERIALS AND METHODS
Patients and Samples
The study populations consisted of patients and control
groups enrolled in a previously conducted NK cell study
(CAPRI-NK/ANRS12153) (10), linked with the CAMELIA
clinical trial (ANRS 1295-CIPRA KH001-DAIDS-ES ID
10425). The CAMELIA clinical trial was a prospective,
randomized, multicenter, open-label, two-arm superiority
trial conducted in Cambodia that demonstrated significant
improvement in survival when ART was started 2 vs. 8
weeks following TB-therapy initiation. TB infection was
diagnosed by a positive smear for acid-fast bacilli and was
confirmed by culture for any clinical sample. TB-IRIS was
defined as the unexplained worsening or re-occurrence of
symptoms or signs of TB after ART initiation (e.g., fever,
dyspnea, lymph-node involvement, or exacerbation of
the diseases at other extra-pulmonary sites), as described
elsewhere (5).
To avoid potential bias due to the different timing of ART
initiation, 48 of the 128 HIV/TB co-infected patients who had
received 2 weeks of TB therapy were randomly selected before
ART initiation. Of the 48 HIV+/TB+ patients, 21 experienced
TB-IRIS during the follow-up. Three control groups were also
considered and served as the baseline for comparison: 11 adult
healthy donors (HD) who were HIV serology negative and had
no evidence of TB, 26 HIV-infected patients naïve of ART with
no evidence of TB (HIV+/TB–) and 23 HIV serology negative
TB positive patients (HIV–/TB+).
Gamma-delta T cells and associated subsets from HIV+/TB+
patients were assessed in cryo-preserved peripheral blood
mononuclear cells (PBMCs) collected during the CAPRI-
NK/ANRS12153 study at the time of ART initiation (week 2 of
TB therapy), week 6 of ART (week 8 of TB therapy), and at IRIS
diagnosis. Measurements were performed at the time of ART
initiation for the HIV+/TB- group and at week 2 of TB therapy
for the HIV–/TB+ group.
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Ethics Statements
This study was carried out in accordance with the
recommendation of “French National Agency of Research
on HIV/AIDS and Viral Hepatitis” Ethic Charter for Research
version 2017 with written informed consent from all patients. All
the patients gave written informed consent in accordance with
the Declaration of Helsinki. The CAPRI-NK (ANRS 12153) study
was approved by the “Cambodian National Ethics Committee
for Health Research.” All participants gave their approval for
the participation in the study by signing the dedicated informed
consent form prior to any study procedure.
Flow Cytometry Analysis
After thawing, PBMCs were stained with a combination of
fluorochrome-labeled monoclonal antibodies for γδ T and iNKT
cells. Expression of surface receptors was measured using a four-
color FACSCalibur II flow cytometer (BD FACSCalibur Flow
Cytometry System, RRID:SCR_000401).
Data acquisition was performed by BD CellQuest Pro (BD
CellQuest Pro, RRID:SCR_014489) and analyzed using FlowJo
Version 7.6.5 (FlowJo, Tree Star, Inc., RRID:SCR_000410).
Gamma-delta (γδ) and δ2posγδpos T cells were defined
as pan-γδTCRpos and δ2posγδpos by staining with anti-pan
γδTCR-PC5 (Beckman Coulter Cat# IM2662, RRID:AB_131175)
and anti-TCRVδ2-FITC (Beckman Coulter Cat# IM1464,
RRID:AB_131019) monoclonal antibodies (mAbs). δ2neg T
cells, including γδ1pos and γδ3pos T cell subsets, was defined
by gating δ2neg population in the total γδpos T cell. Activation
status and repertoire of γδpos and δ2posγδpos T cells were
determined by anti-HLADR-APC (BD Biosciences Cat#
559866, RRID:AB_398674), anti-CD158a, h-PE (KIR2DL1/DS1)
(Beckman Coulter, Cat# A09778, RRID:AB_2801261), anti-
CD158b1/b2, j-PE (KIR2DL2/L3) (Beckman Coulter Cat#
IM2278U, RRID:AB_2728104), anti-NKG2D-PE (CD314)
(Beckman Coulter, Cat# A08934, RRID:AB_2801262), and
anti-NKG2C-APC (CD159c)(R and D Systems Cat# FAB138A,
RRID:AB_416838) mAbs. Gating strategy for γδT cells is shown
in Supplementary Figure 1.
Invariant natural killer T cells were defined using anti-CD3-
FITC (Beckman Coulter Cat# A07746, RRID:AB_2801270)
and anti-Vα24Jα18-APC (Thermo Fisher Scientific Cat#
17-5806-42, RRID:AB_10717252). iNKT cells subsets were
identified using anti-CD56-PC5 (Beckman Coulter Cat#
A07789, RRID:AB_1575976) mAbs, anti-CD4-FITC (BD
Biosciences Cat# 555346, RRID:AB_395751), and anti-CD8-
FITC (BD Biosciences Cat# 347313, RRID:AB_400279).
In order to validate the sample acquisition for cytometry
analysis, at least 100 events were recorded in the iNKT cell
gate. Dead cells were gated out by forward and side scatter.
Invariant natural killer T cell receptors were measured by
staining with anti-NKp46-PE (CD335) (Beckman Coulter
Cat# IM3711, RRID:AB_1575960), anti-CD161-PE (Beckman
Coulter Cat# IM3450, RRID:AB_131250), anti-CD62L-PE
(BD Biosciences Cat# 560966, RRID:AB_2033966), anti-
CCR6-PE (BD Biosciences Cat# 559562, RRID:AB_397273),
and anti-CD69-FITC (Beckman Coulter Cat#IM1943U;
RRID:AB_2801272) mAbs.
The combination of fluorochrome-conjugated monoclonal
antibodies used for immunostaining is shown as
Supplementary Table 1. Representative dot plot of flow
cytometry analysis of the marker expression on gamma
delta T cells and invariant NKT cells is shown in
Supplementary Figures 2E, 8F.
Statistical Analyses
Statistical analysis was performed using GraphPad Prism
software version 6.0e (GraphPad Software In., San Diego, CA,
USA, RRID:SCR_002798). Phenotypic parameters obtained at
baseline were first compared across the five groups by the
Kruskal-Wallis test. If the test showed a significant difference,
pair-wise comparisons were conducted. Phenotypic markers of
IRS patients were compared to age, gender, CD4T cells count
and viral load matched non-IRIS patients using non-parametric
(Mann Whitney U test). A p-value of <0.05 was considered
statistically significant.
RESULTS
Characteristics of Patients
At baseline, no significant differences were noted for sex
(p = 0.83), age (p = 0.32), CD4 T-cell count (p = 0.86), and
HIV-1 RNA viral load (p = 0.50) between TB-IRIS and non-
IRIS patients (Table 1). Moreover, HIV/TB co-infected patients
included in the present analysis had similar characteristics to
those enrolled in the CAPRI-NK/ANRS12153 and CAMELIA
clinical trials (10, 23). CD4 count was significantly lower in
both TB-IRIS and non-IRIS HIV+/TB+ patients vs. HIV+/TB–
patients (both p< 0.05). Although not significantly different, the
HIV RNA plasma load in both TB-IRIS and non-IRIS patients
tended to be higher than that of HIV+/TB– control patients.
γδpos T Cells and δ2posγδpos T Cell Subset
in TB-IRIS
The proportion of γδpos T cells and δ2posγδpos T cells was not
different between TB-IRIS and non-IRIS patients at baseline
(Figure 1A and Supplementary Figure 3A). However, both the
level of δ2posγδ posT cells and the ratio of δ2posγδpos: δ2negγδposT
cells were significantly lower in HIV and/or TB-infected patients
vs. HD (Figures 1A,B). Moreover, δ2posγδpos: δ2negγδposT cell
ratio tended to be lower in TB-IRIS vs. non-IRIS patients
[median (25–75% IQR): 0.69% (0.28–1.52) vs. 1.52% (0.31–
2.91)] (p = 0.21), and HIV–/TB+ patients [median [(25–75%
IQR): 1.65% (0.48–4.97)] (p = 0.26) (Figure 1B); however, the
frequency of δ2negγδposT cells in TB-IRIS and non-IRIS patients
was not significantly different (Supplementary Figure 6A).
Activation of γδposT Cells and δ2posγδpos
T Cell Subset in TB-IRIS Patients
Immune activation is a common feature of both HIV and TB
infections, and elevated immune activation could play a role in
the physiopathology of IRIS. Thus, we measured the level of
HLA-DR as a marker of γδ T cell activation.
At the time of ART initiation, HIV/TB co-infected
patients showed significantly higher levels of HLA-DR on
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TABLE 1 | Baseline characteristics of patients.
HIV+/TB+ IRIS
(n = 21)
HIV+/TB+ non-IRIS
(n = 27)
HIV+/TB–
(n = 24)
HIV–/TB+
(n = 22)
HIV–/TB–
(n = 11)
Gender
Female n (%) 10 (47.6) 12 (44.4) 16 (61.5) 3 (13.6) 4 (36.3)
Male n (%) 11 (52.38) 15 (55.56) 10 (38.46) 19 (86.36) 7 (63.64)
Age (years)
Median (IQR) 33 (28–38) 35 (29–43) 33 (30–41) 41 (32–56) 28 (25–38)
CD4 (cells/mm3)
Median (IQR) 31 (17–51) 27 (18–108) 89 (20–167)* – –
HIV-1 RNA VL (log10cp/mL)
Median (IQR) 5.7 (5.3–5.8) 5.6 (5.0–5.8) 5.0 (4.5–5.9) – –
IQR, Interquartile range. *p < 0.05.
FIGURE 1 | δ2posγδposT cells and the ratio of δ2posγδpos: δ2negγδposT cell in TB-IRIS, and non-IRIS at baseline. The proportion of δ2posγδpos T cell (A), the ratio of
δ2posγδpos: δ2negγδpos T cell (B) in TB-IRIS, non-IRIS, and control groups: [TB (TB+/HIV–), HIV (HIV+/TB–), HD (HIV–/TB–)] are shown. Results are expressed as
median and 25–75% interquartile range. Significant p-values (p < 0.05) are indicated.
total lymphocytes, γδposT cells, and the δ2posγδposT cell
subset vs. HD (Figures 2A,B and Supplementary Figure 3D).
Comparatively, TB-IRIS patients had significantly increased
HLA-DR expression in δ2posγδposT cell subset vs. those that were
non-IRIS, HIV+/TB– or HIV–/TB+. There was no significant
difference in HLA-DR expression on δ2negγδposT cells between
TB-IRIS and non-IRIS patients (Supplementary Figure 6B).
However, levels of HLA-DR were significantly higher [median
(25–75% IQR): 13.5 (7.5–26.0)] in TB-IRIS patients than HIV–
/TB+ patients (p = 0.004) and HD (p = 0.04) and tended to be
higher than in non-IRIS [median (25–75% IQR): 9.8 (6.3–17.4)]
and HIV+/TB– patients (Supplementary Figure 6B).
We next examined the evolution of γδpos T cell activation
from the time of ART initiation to the IRIS event. Samples from
eight TB-IRIS patients and six non-IRIS controls were available
for longitudinal analysis. Expression of HLA-DR on γδpos T cells
significantly decreased from baseline to the onset of IRIS in TB-
IRIS patients (p= 0.02), whereas it remained unchanged in non-
IRIS patients (Supplementary Figure 4A). In addition, the delta
value of HLA-DR on γδpos T cells from baseline to IRIS onset
tended to be lower than those observed in non-IRIS patients
(p= 0.06) (Supplementary Figure 4B).
NKG2D and NKG2C Expression on γδpos
T Cells in HIV/TB Co-infected Patients
Gamma-delta T cells share many features with NK cells,
including the expression of activating and inhibitory NK-
cell receptors as well as cytotoxic functionality. Therefore, we
assessed NKG2D and NKG2C expression on γδpos T cells during
TB-IRIS (Figures 3A,B and Supplementary Figures 3E, 5, 6C).
NKG2D is a C-type lectin-like NK receptor that recognizes
cellular stress protein-ligand MICA-B and ULBP. Expression of
NKG2D receptors on γδT cells play a role in co-stimulating TCR-
mediated activation, resulting in pro-inflammatory cytokine
production and cytotoxic activity (24). Representative flow plots
are shown in Supplementary Figures 2C,D. Although NKG2D
expression on total γδpos (Supplementary Figure 3E), δ2posγδpos
(Figure 3A) and δ2neg γδpos T cells (Supplementary Figure 6C)
was not significantly different between IRIS and non-IRIS
patients at baseline, NKG2D levels of IRIS patients were lower
than those in the control groups, and IRIS patients exhibited
lower median values vs. non-IRIS patients. At IRIS onset,
NKG2D expression on the surface of γδpos T cells and δ2posγδpos
T cells was not significantly different between IRIS and non-IRIS
control (Supplementary Figures 5A,B). The observed decrease
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FIGURE 2 | HLA-DR expression on δ2posγδpos T cell, and total lymphocytes in TB-IRIS, and non-IRIS at baseline. The proportion of HLA-DRposδ2posγδpos T cell (A),
HLA-DRpos on total lymphocytes (B) in TB-IRIS, non-IRIS, and control groups [TB (TB+/HIV–), HIV (HIV+/TB–), HD (HIV–/TB–)] are shown. The results are median
and 25–75% interquartile range. Significant p-values (p < 0.05) are indicated.
FIGURE 3 | NKG2D, and NKG2C expression on δ2posγδpos T cell in TB-IRIS and non-IRIS at baseline. The proportion of NKG2Dposδ2posγδpos T cell (A),
NKG2Cposδ2posγδpos T cell (B) in TB-IRIS, non-IRIS, and control groups [TB (TB+/HIV–), HIV (HIV+/TB–), and HD (HIV–/TB–)] are shown. The results are median and
25–75% interquartile range. Significant p-values (p < 0.05) are denoted.
in expression of NKG2D on γδT cells in HIV and/or TB infection
has been previously described (10, 25, 26).
NKG2C is the killer cell lectin-like receptor C2 (KLRC2)
specific for HLA-E. Changes in expression of NKG2C has
been reported in HIV-infected and TB patients (27, 28).
NKG2C expression on γδpos T cells and the δ2posγδpos T
cell subset was low in all patient groups as well as in HD
(Figure 3B and Supplementary Figure 3F). However, it was
higher for the patients whatever infection vs. HD. Levels of
NKG2C on δ2negγδpos T cells were similar for all groups
(Supplementary Figure 6D).
Killer Cell Immunoglobulin-Like Receptors (KIRs):
CD158a and CD158b on γδ T Cells in TB-IRIS
KIRs regulate γδ T cell activation and function (29). Moreover,
changes in KIR gene expression are related to the evolution of
HIV infection (30–32). KIR expression on γδ T cells was reported
to be reduced in IRIS vs. non-IRIS patients in a European cohort
(11). Therefore, we measured KIR expression on γδ T cells in our
patient cohort.
At baseline, expression of CD158a on total γδpos T cells
(Supplementary Figure 3B) close to be significant in TB-IRIS
patients vs. non-IRIS[median (25–75% IQR): 12.40 (7.78–19.60)
vs. 6.30 (2.94–14.50), p = 0.05]; however, CD158a expression
on γδpos T cells was significantly higher for TB-IRIS patients
than HD [median (25–75% IQR): 4.45 (1.68–8.30)] (p =
0.001). Further, CD158a expression on δ2pos γδpos T cells was
significantly higher in TB-IRIS patients [median (25–75% IQR):
10.90 (3.82–22.30)] than in non-IRIS patients [(median (25–75%
IQR): 3.56 (1.38–10.20)] (p = 0.02), HIV+/TB– patients (p =
0.003), and HD (p= 0.001) (Figure 4A). There was no difference
in CD158b expression on γδpos T cells or the δ2posγδpos T cell
subset between TB-IRIS and non-IRIS patients (Figure 4B and
Supplementary Figure 3C). Nevertheless, CD158b expression
on γδpos and δ2posγδpos T cells tended to be higher for all
infected patients vs. HD. Representative flow plots of CD158a
and CD158b expression on γδpos T cells and the δ2 subsets are
shown in Supplementary Figures 2A,B.
Invariant NK T Cells in HIV/TB Co-infected
Patients
Several different approaches have been used to identify invariant
Natural killer T cells (iNKT) in the literature (18); however, the
anti-Vα24Jα18 CDR3 loop TCR monoclonal antibody (6B11)
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FIGURE 4 | Killer Immunoglobulin-like receptors CD158a, and CD158b expression on δ2posγδpos T cell subset in TB-IRIS and non-IRIS at baseline. The proportion of
CD158aposδ2posγδpos T cell (A), CD158bposδ2posγδpos T cell (B) in TB-IRIS, non-IRIS, and control groups [TB (TB+/HIV–), HIV (HIV+/TB–), and HD (HIV–/TB–)] are
shown. The results are median and 25–75% interquartile range. Significant p-values (p < 0.05) are denoted.
FIGURE 5 | The phenotype of circulating invariant NKT cells and CD56+NKT cell subset in TB-IRIS and non-IRIS at baseline. The proportion of circulating
Vα24Jα18+ iNKT cells (A), or CD56+Vα24Jα18+ iNKT cells among total CD3+ T cells (B); and proportion of CD8+ iNKT cells among total Vα24Jα18+ iNKT cells
(C) or CD8+CD56+ iNKT cells among Vα24Jα18+CD56+ (D), in TB-IRIS, non-IRIS, and control groups [TB (TB+/HIV–), HIV (HIV+/TB–), and HD (HIV–/TB–)] are
shown. The results are shown as median and 25–75% interquartile range. Significant p-values (p < 0.05) are indicated.
has been suggested to be highly specific for the identification of
human iNKT cells (33). In addition, a portion of CD3+iNKT
cell express CD56, and this cell subset has been reported to be
cytotoxic and produce regulatory cytokines (34).
iNKT cells and iNKT cell subsets were defined by the co-
expression of CD3 and Vα24Jα18. The gating strategies for
analysis of whole and CD56+iNKT cell subset are shown
Supplementary Figure 7.
Number of iNKT cells and CD56+iNKT cells were lower in
all groups of infected patients vs. HD (p ≤ 0.05) (Figures 5A,B).
Both total iNKT cells and CD56+iNKT cells were similar at
baseline between TB-IRIS and non-IRIS patients.
Although both CD8+iNKT cell and CD8+CD56+NKT cell
subset levels were not a difference between TB-IRIS and
non-IRIS, they were decreased in Mtb infected patients and
were significantly different between IRIS (Figures 5C,D). Also,
CD4+iNKT cells at baseline were not the different between TB-
IRIS and non-IRIS. However, CD4+iNKT cells and the ratio of
CD4+iNKT: CD8+iNKT was lower in HIV and/or TB infection
than HIV–/TB+ and HD (Supplementary Figures 9A,B).
Frontiers in Immunology | www.frontiersin.org 6 August 2019 | Volume 10 | Article 2018
Pean et al. γδ T Cells and iNKT Cells in TB-IRIS
FIGURE 6 | CD69, and CD161 expression on iNKT cells and CD56+ iNKT cell subset in TB-IRIS and non-IRIS at baseline. The proportion of CD69 expression on
CD3+Vα24Jα18+ iNKT cells (A), and on CD56+CD3+Vα24Jα18+ (B); the proportion of CD161 expression on Vα24Jα18+ iNKT cells (C), and on
CD56+CD3+Vα24Jα18+ iNKT cells (D) in TB-IRIS, non-IRIS, and control groups [TB (HIV–/TB+), HIV (HIV+/TB–), and HD (HIV–/TB–)] are shown. The results are
median and 25–75% interquartile range. Significant p-values (p < 0.05) are presented.
We also studied the activation of iNKT cells and CD56+iNKT
cells by measuring the expression of several markers. CD69
levels at baseline were similar between TB-IRIS and non-IRIS
patients, HIV/TB co-infected patients had increased number
of both activated iNKT cells and CD56+iNKT cells compared
to mono-infected TB or HIV patients (Figures 6A,B). Further,
expression of CD161 on iNKT cell and CD56+iNKT cells did
not differ between TB-IRIS and non-IRIS patients. However,
CD161 expression on both iNKT cells and CD56+iNKT
cells was higher in mono-infected HIV or HIV/TB patients
vs. HD (Figures 6C,D). No significant differences in the
expression of NKp46, CCR6, CD62L on CD56+iNKT cells
subset were observed. Representative flow plots are depicted in
Supplementary Figure 8.
DISCUSSION
Diagnosis of TB-IRIS is currently based purely on clinical
findings. Thus, a better understanding of the physiopathology
and risk of TB-IRIS in HIV/TB co-infected patients is vital for
the development of prognostic or predictive tests. While the
restoration of immunity, particularly T cell immunity, against
Mtb is often cited as playing a central role in TB-IRIS, evidence
is contradictory and other immune cells may play a vital role in
syndromic development. Several lines of evidence indicate that
innate immunity plays a crucial role in TB-IRIS. For example,
abundant infiltration of CD68+ macrophages was observed in
the post-mortem lung tissue from a confirmed TB-IRIS case
(35). In addition, a high level of caspase-1 expression by CD64+
monocytes and elevated plasma IL-1β and IL-18 levels have been
reported (36), along with elevated levels of IL-6 and C-reactive
protein (8, 37, 38). TLR and TREM-1-induced inflammasome
signaling have also been reported to be up-regulated in TB-IRIS
patients (8). In addition to monocytes/macrophages, NK cells
and invariant natural killer T cells may also contribute to the
pathogenesis of TB-IRIS (9, 10, 22, 36). Patients with unmasking
TB-IRIS have increase NK cell activation and IL-8 expression vs.
non-IRIS or HIV-1-mono-infected controls. Our previous results
show a large increase in NK cell activity associated with TB-IRIS,
further bringing to light the role of innate immunity in IRIS
(10). Others have subsequently confirmed these results (9, 22, 36).
Further, modification of the γδ T cell repertoire (11) and an
elevated proportion of iNKT cell have been reported in TB-IRIS
patients (11, 22). Therefore, we extended our NK cell study to γδ
T cells and iNKT cells.
In our study, the proportion of peripheral γδposT cells did
not differ at baseline between TB-IRIS and non-IRIS patients;
however, there was a significantly higher expression of HLA-
DR on γδposT cells and δ2posγδposT cells at baseline in TB-
IRIS patients. Consistent with previous reports, our results
demonstrate that TB-IRIS patients have highly activated γδposT
cells and δ2posγδposT cells at baseline, and that immune
activation is higher in HIV/TB co-infection vs. TB or HIV
mono-infection alone (39). Moreover, we show an increase in
CD158a (KIR2DL1/DS1) expression on γδposT cells in TB-IRIS
patients. We did not find any difference between iNKT cells and
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CD56+iNKT cells in TB-IRIS and non-IRIS patients at baseline.
Due to the limitations of the retrospective nature of our study
and precious sample sizes, we, unfortunately, cannot extend our
conclusions. Further work will be conducted to include a greater
number of markers and the function of the different cell types.
Moreover, the evolution of these markers will be followed in
detail at more time points. The evolution of HLA-DR on γδpos
T cells from baseline to IRIS time (week 8 of ART) significantly
declined in IRIS patients. Although the levels of HLA-DR on
γδpos T cells were lower in non-IRIS patients at baseline, we also
observed a non-significant decrease of activated γδpos T cells.
However, the small number of samples tested might be limited to
see a significant difference. This decrease could be explained by
the effect of ART in both groups of patients. However, we cannot
exclude the role of regulatory populations in the IRIS group.
As previously described (40–42), we also observed decreased
proportions of δ2posγδposT cells, decreased expression of NKG2D
on γδposT cells, and depletion of both iNKT cells and
CD56+iNKT cells in TB and/or HIV infected patients vs. HD,
regardless of the infection condition.
Gamma-delta T cell activation is a known feature of active
tuberculosis and is also observed in HIV/TB co-infected patients
(11, 42). In a European setting, Bougarit et al. reported higher
levels of δ2posγδposT cells in TB-IRIS patients. Furthermore,
they found that this subset exhibited strong IFN-γ production.
They thus postulated that δ2posγδposT cell populations could
be involved in TB-IRIS via the secretion of pro-inflammatory
cytokines (11). Here, we observed a trend toward lower levels
of δ2posγδposT cells in TB-IRIS subjects, although it was
not significant. It has been shown that interactions between
γδposT cells, NK cells, DCs can control immune activation and
inflammation. δ2posγδposT cells play an important role in human
immunity to M. tuberculosis and HIV-1. Defects in one type
of these cell types can lead to an imbalance in the cross-talk
between γδ T cells, NK cells, and DCs and consequently a
loss of control in immune activation and inflammation (43–
45). Our data showed significantly increased levels of γδposT cell
and δ2posγδposT cell activation at baseline. Mtb antigens could
be partly responsible for this activation. Moreover, δ2posγδposT
cells dysfunction has been described in tuberculosis and HIV-
1 infection (42). However, this result differs from the findings
of Bourgarit et al. who did not find any difference between TB-
IRIS and non-IRIS patients in terms of HLA-DR expression on
γδ T cells in a French population. This conflicting result could
be explained by the fact that basal innate immune activation
in HIV/TB co-infected Cambodian patients is higher than that
observed in European patients (11). Moreover, the background
stimulation of innate immunity by local endemic pathogens
could also play a role. Future studies will test the functional
capacity of γδ T cells from Cambodian patients for comparison.
Modulation of NKG2D expression in TB and HIV/TB co-
infected patients has previously been described (26, 46), and
correlates with a loss of NK cell function (10, 47). Decreased
expression of NKG2D on δ2posγδposT cell at baseline in TB/HIV
infected patients could be explained by the increased level of
NKG2D ligands on TB infected macrophages (48), leading to
the internalization of NKG2D receptors (25, 49, 50). However,
a limitation of our study was the absence of soluble NKG2D
ligand measurements (50). Nevertheless, we did not observe the
lower expression of NKG2D on δ2pos γδposT cells at the time
of TB-IRIS diagnosis, suggesting the restoration of γδ T-cell
functions (51, 52).
Perhaps, the most intriguing result from this study is of
the increased CD158a (KIR2DL1/DS1) expression on δ2posγδpos
T cells in patients who develop TB-IRIS. CD158a has both
inhibitory and activating properties. Expression of this KIR
correlates with better control of HIV replication (31, 53).
Interestingly, our data contrast with those obtained in another
study that reports a higher baseline proportion of δ2posγδpos T
cells lacking KIR expression in TB-IRIS patients (11). However,
we cannot distinguish between activating or inhibitory KIRs,
making the interpretation of this result difficult. As modulation
of KIR expression has been described during HIV infection
(30–32), the increase in CD158a expression in TB-IRIS patients
could be related to better preservation of γδ T cells, as we
already showed for NK cells (10). A detailed study of γδ
T cell populations will be necessary to better define their
role in TB-IRIS.
Invariant NKT and CD3+CD56+NKT cells subset have also
been previously described in HIV and/or TB infected patients
(34, 54, 55). One study suggests depletion iNKT cells occurs
early in HIV infection, and that this loss appears to be persistent
(56). In contrast to HIV infection alone, one report suggests an
increase in iNKT cell levels associated with increased plasma
levels of granzyme B and perforin in IRIS patients (22, 57). This
increase could be due to a rapid recovery of iNKT cells by ART
(58); however, we did not observe any difference between TB-
IRIS and non-IRIS in terms of the proportion of iNKT cells
and CD56+iNKT cells, their level of maturation, or activation at
baseline of TB-IRIS onset. These results suggest that there is no
association between iNKT cells and TB-IRIS development in the
context of our cohort.
The interaction of the CD161 receptor with its ligand, lectin-
like transcript−1 (LLT-1), has been reported to have both
inhibitory and co-stimulatory effects (59) and has been associated
with IFN-γ and IL-17 secretion by CD4+ T cells (60). We
observed lower levels of iNKT cells, regardless of the infection
(HIV or TB), vs. HD. This finding was not surprising, as
depletion of peripheral-blood iNKT cells has been reported
in several studies (21, 61). However, the mechanisms of such
depletion are not well-understood. A study conducted in HIV-
infected patients proposed that depletion of iNKT cells could
be related to the apoptosis induced by the Fas/FasL pathway
(62). In the context of Mtb infection, the decrease of peripheral
iNKT cells could be due to their migration to the lung, where
they contribute to granuloma formation (21). In addition, we
observed increased expression of CD161 and CD69 on iNKT cells
of HIV/TB co-infected patients. These results are consistent with
those of Snyder-Cappione et al., who found that the frequency
of NKT cells expressing CD161 negatively correlated with the
production of both TNF-α and IFN-γ (61). Also, it has been
demonstrated that innate CD4+Vα24+ NKT cells regulated by
IL-7 typically produce Th1- and Th2-associated cytokines (63).
The depletion and functional impairment of CD4+iNKT cells
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and CD8+ iNKT cells during HIV infection have been described
in several studies (21). We did not measure iNKT cell activity
but it is possible that the cytokine-producing capacity of iNKT
cells could be impaired during chronic HIV/TB co-infection
and related to the decrease of total iNKT cells observed in
infected patients.
Our results provide further evidence for the involvement of
innate immunity in the pathogenesis of IRIS in HIV/TB co-
infected patients. More studies on the role of innate immunity
could be beneficial in the search for biomarkers of TB-IRIS.
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